Patient Identity
Patient Identity: Confidential (Name & personal details masked for privacy)
Age/Gender: 68 Years / Male
Location: Pune, Maharashtra
Treating Physician: Professor Dr. Shailesh Phalle, MD (Ayurveda)
Clinic: Ayusanjivani Ayurveda Clinic, Pune
Patient Background
A 68-year-old male presented to Ayusanjivani Ayurveda Clinic in February 2026 with newly
diagnosed Type 2 Diabetes Mellitus (Madhumeha). The patient was not on any oral hypoglycemic drugs or insulin therapy at the time of consultation.
Presenting Complaints
- Elevated blood sugar levels
- Mild fatigue
- Generalized weakness
- History of eczema
- Disturbed metabolism
Initial Ayurvedic Assessment
Nadi Pariksha
- Vata-Pitta dominant pulse
Prakriti & Vikriti
| Parameter | Observation |
|---|---|
| Prakriti | Vata-Pitta |
| Vikriti | Vata aggravation |
| Agni | Mandagni |
| Diagnosis | Madhumeha |
Baseline Investigations (February 2026)
| Test | Result |
|---|---|
| HbA1c | 8.7% |
| Fasting Blood Sugar | 141 mg/dL |
| Vitamin B12 | 149 pg/mL |
| Vitamin D3 | 10.8 ng/mL |
Ayurvedic Treatment Protocol
Internal Medicines
Madhusanjivani Granules
Key Ingredients:
- Gudmar
- Mahamejva
- Katuki
- Chirayata
- Karela
- Indrajav
- Amla
- Gokshur
- Haritaki
- Jambibija
- Methi
- Neem Patra
- Chandraprabha
- Aarogyavardhini
- Haridra
- Devdar
- Daruhaldi
- Nagarmotha
- Shuddha Shilajit
- Galo
Additional Medicines
- Mamejva Vati
- Shiva Tablet
- Dibocare Capsule
- CP Gold Tablet
- Lifestyle Advice
- Diabetic diet counseling
- Daily walking and exercise
- Weight management
- Regular monitoring of blood sugar
- Pathya-Apathya education
Progress During Follow-Up
HbA1c Trend
| Date | HbA1c |
|---|---|
| Feb 2026 | 8.7% |
| Mar 2026 | 7.5% |
| Apr 2026 | 6.7% |
| May 2026 | 6.5% |
| Jun 2026 | 6.1% |
Total Reduction
8.7% → 6.1%
Absolute Reduction: 2.6% HbA1c
Fasting Blood Sugar Trend
| Date | FBS (mg/dL) |
|---|---|
| Feb 2026 | 141 |
| Mar 2026 | 113 |
| Apr 2026 | 113 |
| May 2026 | 108 |
| Jun 2026 | 114 |
Post-Prandial Blood Sugar Trend
| Date | PPBS |
|---|---|
| Apr 2026 | 135 mg/dL |
| May 2026 | 134 mg/dL |
| Jun 2026 | 108 mg/dL |
Before vs After Results
Before
After
| Parameter | Before Treatment | After Treatment | Improvement |
|---|---|---|---|
| HbA1c | 8.7% | 6.1% | ↓ 29.8% |
| Fasting Sugar | 141 mg/dL | 114 mg/dL | ↓ 27 mg/dL |
| Post Meal Sugar | 135 mg/dL | 108 mg/dL | ↓ 27 mg/dL |
| Weight | 78.8 kg* | 74.8 kg | ↓ 4 kg |
| Fatigue | Present | Improved | Significant |
| Digestion | Average | Good | Improved |
Clinical Outcome
After approximately four months of individualized Ayurvedic treatment:
✓ HbA1c reduced from diabetic range (8.7%) to near-controlled range (6.1%)
✓ Fasting and post-prandial glucose improved significantly
✓ Weight reduction of approximately 4 kg achieved
✓ Energy levels improved
✓ Digestion improved
✓ No insulin therapy required
✓ Better overall metabolic control
Discussion
According to Ayurveda, Madhumeha is primarily associated with derangement of Kapha,
Meda, and later Vata involvement. In this case, a Vata-dominant presentation was observed.
The treatment approach focused on:
- Deepana-Pachana
- Agni correction
- Medohara action
- Kapha-Vata balancing
- Rasayana support
- Dietary and lifestyle modifications
The combination of herbal formulations, strict dietary compliance, and regular follow-up
contributed to the sustained improvement in glycemic parameters.
Conclusion
This case demonstrates substantial improvement in glycemic control in a newly diagnosed
Type 2 Diabetes patient managed through a personalized Ayurvedic treatment plan under the
supervision of Professor Dr. Shailesh Phalle. HbA1c improved from 8.7% to 6.1% within
four months, accompanied by improved fasting and post-meal blood glucose levels and
better overall well-being.
Author
Professor Dr. Shailesh Phalle, MD (Ayurveda), Ayusanjivani Ayurveda Clinic, Pune
Medical Reviewer
Professor Dr. Shailesh Phalle, MD (Ayurveda)
Disclaimer
This is an individual patient case study. Results may vary from person to person depending
upon disease duration, constitution, diet, lifestyle, compliance, and associated medical
conditions. Patients should consult a qualified healthcare professional before starting or
stopping any treatment.
